Corporate Compliance

Adventis pays more than $190 million in settlement

Healthcare Auditing Weekly, September 25, 2007

Adventis Pharmaceuticals, Inc. has agreed to pay more than $190 million to settle FCA allegations related to its pricing of the drug Anzemet. The government alleged that Adventis set and maintained inflated prices for Anzemet knowing that government healthcare programs established reimbursement rates based on those prices.

"The Justice Department will continue to hold drug companies accountable for fraudulent pricing schemes designed to give windfalls to drug companies and doctors at the expense of federal healthcare programs for the poor and elderly," said Assistant Attorney General Peter D. Keisler.

Click here to read the original press release.

    Strategies for Health Care Compliance
  • Strategies for Health Care Compliance

    News and real-life examples to increase the effectiveness of your compliance program. Strategies for Health Care Compliance...

  • Compliance Monitor

    This HTML e-mail newsletter delivers news on Medicare and Medicaid fraud and abuse, as well as recent documents and targets...

  • Medicare Weekly Update

    Each issue of Medicare Weekly Update includes the latest CMS proposed and final rules, CMS manual revisions, and...

  • Medicare Update for Physician Services

    Medicare Update for Physician Services is a free, monthly e-zine that delivers news and information to help physician...

Most Popular

Related Articles